Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions

Aydoğan, Ümit; Aydoğdu, Aydoğan; Akbulut, Halil; Sönmez, Alper; Yüksel, Servet; Başaran, Yalçın; Uzun, Özcan; Bolu, Erol; Sağlam, Kenan

doi:10.1507/endocrj.ej12-0134

Cited by 88 publications

(91 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…97,98 Furthermore, small studies have shown increased anxiety and depression among adolescents with CHH and, as such, these symptoms merit attention. 99,100 The clinical heterogeneity of CHH makes differentiation from CDGP, which is usually associated with short stature, poor growth velocity and delayed skeletal maturation, difficult. 90,95 The presence of micropenis and/or cryptorchidism argues firmly in favour of CHH, as these features are rarely seen in CDPG.…”

Section: Adolescentmentioning

confidence: 99%

European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment

et al. 2015

View full text Add to dashboard Cite

| Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder caused by the deficient production, secretion or action of gonadotropin-releasing hormone (GnRH), which is the master hormone regulating the reproductive axis. CHH is clinically and genetically heterogeneous, with >25 different causal genes identified to date. Clinically, the disorder is characterized by an absence of puberty and infertility. The association of CHH with a defective sense of smell (anosmia or hyposmia), which is found in ~50% of patients with CHH is termed Kallmann syndrome and results from incomplete embryonic migration of GnRHsynthesizing neurons. CHH can be challenging to diagnose, particularly when attempting to differentiate it from constitutional delay of puberty. A timely diagnosis and treatment to induce puberty can be beneficial for sexual, bone and metabolic health, and might help minimize some of the psychological effects of CHH. In most cases, fertility can be induced using specialized treatment regimens and several predictors of outcome have been identified. Patients typically require lifelong treatment, yet ~10-20% of patients exhibit a spontaneous recovery of reproductive function. This Consensus Statement summarizes approaches for the diagnosis and treatment of CHH and discusses important unanswered questions in the field.

show abstract

Section: Adolescentmentioning

confidence: 99%

European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Gonadotrophin deficiency leading to hypogonadism also impairs QoL compared to age-standardized general population (27,28,29,30). In males, low testosterone is associated with physical impairment (i.e., reduced muscle strength or osteoporosis), as well as psychological disturbances (depression, anxiety and sexual dysfunctions like decreased libido), often associated to infertility which is another common complaint, all of which negatively impact on QoL (29).…”

Section: Hypopituitarism (Including Growth Hormone Deficiency)mentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Webb

Crespo

Santos

et al. 2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: In the last few years, quality of life (QoL) has become an outcome measure in patients with pituitary diseases. Objective: To describe the available data on QoL impairment evaluated with questionnaires in patients with pituitary diseases. Design: Critical review of the pertinent literature and pragmatic discussion of available information. Methods: Selection of relevant literature from PubMed and WOK, especially from the last 5 years and comprehensive analysis. Results: QoL is impaired in all pituitary diseases, mostly in acromegaly and Cushing's disease (similar to other causes of Cushing's syndrome), but also in non-functioning pituitary adenomas and prolactinomas, especially in the active phase of the disease. Nevertheless, even after endocrine 'cure', scores tend to be below normative values, indicative of residual morbidity after hormonal control. The presence of hypopituitarism worsens subjective QoL perception, which can improve after optimal substitution therapy, including recombinant human growth hormone, when indicated. Conclusions: To improve the long-term outcome of pituitary patients, helping them to attain the best possible health, it appears desirable to include subjective aspects captured when evaluating QoL, so that the affected dimensions are identified and if relevant treated. Additionally, being aware that treatment outcome may not always mean complete normalisation of physical and mental issues related to QoL can be a first step to adaptation and conforming to this new status.

show abstract

“…3 Muscle weakness and low bone mass, Depression, anxiety loss of libido, and erectile dysfunction and decreased quality, abnormal lipid profile, CVS pathophysiologic change. [4][5][6][7] The association between low serum testosterone (LST) and diabetes (DM) has recently received substantial attention; studies have reported that male patients with Thus, it is unclear which the risk factors correlates in DM are associated with MHG, Therefore, it is especially important to explore the risk factors for hypogonadism to facilitate prevention, early diagnosis, and early treatment. The aim of this study was to determine the prevalence of male hypogonadism among Egyptian patients with type 2 diabetes and to identify the risk factors may be associated with low serum testosterone concentrations in men with type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6][7] The association between low serum testosterone (LST) and diabetes (DM) has recently received substantial attention; studies have reported that male patients with ABSTRACT Background: Diabetes mellitus (DM) affects an estimated 285 million people worldwide. This number is expected to reach 438 million by the year 2030.…”

mentioning

confidence: 99%

Prevalence and predictors for low total testosterone levels among male type 2 diabetic patients: an Egyptian experience

Aboelnaga

Elshahawy

2016

Int J Res Med Sci

View full text Add to dashboard Cite

INTRODUCTIONDiabetes mellitus (DM) affects an estimated 285 million people worldwide. This number is expected to reach 438 million by the year 2030.1 On the other hand, Male hypogonadism (MHG) is a clinical syndrome that results from failure to produce physiological concentrations of testosterone. 2MHG is significantly associated with various comorbidities reduced libido, erectile dysfunction, increased adiposity, low energy and fatigue.3 Muscle weakness and low bone mass, Depression, anxiety loss of libido, and erectile dysfunction and decreased quality, abnormal lipid profile, CVS pathophysiologic change. [4][5][6][7] The association between low serum testosterone (LST) and diabetes (DM) has recently received substantial attention; studies have reported that male patients with ABSTRACT Background: Diabetes mellitus (DM) affects an estimated 285 million people worldwide. This number is expected to reach 438 million by the year 2030. The aim of this study was to determine the prevalence of male hypogonadism among Egyptian patients with type 2 diabetes and to identify the risk factors may be associated with low serum testosterone concentrations in men with type 2 diabetes. Methods: 140 male patients with type 2 diabetes were recruited in this cross-sectional study. This study WAS conducted from January 2012 to January 2016 in the endocrinology and metabolism unit, Mansoura University, Egypt. Results: We found 48 (34.2%) patients with hypogonadism (defined as TT ≤300 ng/dl) among 140 male patients with type 2 diabetes. 7 out of 48 (14.5%) patients with TT ≤300 ng/dl had high abnormal gondotrophins hormones levels while 41 patients out of 48 (85.5%) had normal gondotrophins hormones levels. We found BMI, WC, Hba1c, UACR, retinopathy ratio, nephropathy ratio, smoker ratio and patient on insulin therapy ratio were increased in the low TT group with statistically significance, but non statistically significant difference in age, diabetic duration, FSH, LH, Prolactin and lipid profile. In this study by using Pearson correlation, we found a statistically significant correlation between TT levels with BMI, WC, FSH, LH, Hba1c, and UACR (P value<0.05). Also by using stepwise multiple regression analysis, we found BMI, WC, LH, Hba1c, and UACR were statistically significant predictors of TT levels. In logistic regression analysis, we found Hba1c, UACR, and WC were statistically significant risk factors for MHG. Conclusions: Visceral obesity, higher Hba1c, and degree of albuminuria are independent risk factors for hypogonadism in Egyptian male patients with type 2 diabetes.

show abstract

Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions

Cited by 88 publications

References 24 publications

European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment

European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Prevalence and predictors for low total testosterone levels among male type 2 diabetic patients: an Egyptian experience

Contact Info

Product

Resources

About